2023
A pilot randomized controlled trial of ketamine in Borderline Personality Disorder
Fineberg S, Choi E, Shapiro-Thompson R, Dhaliwal K, Neustadter E, Sakheim M, Null K, Trujillo-Diaz D, Rondeau J, Pittaro G, Peters J, Corlett P, Krystal J. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology 2023, 48: 991-999. PMID: 36804489, PMCID: PMC10209175, DOI: 10.1038/s41386-023-01540-4.Peer-Reviewed Original ResearchConceptsBorderline personality disorderSecondary outcome measuresOutcome measuresSocio-occupational functioningSuicidal ideationPilot studyTrial of ketaminePersonality disorderInfusion of ketaminePrimary outcome measureEffects of ketamineMidazolam groupAdverse eventsKetamine groupClinical benefitMood symptomsKetamineFDA approvalDrug midazolamInfusionBPD symptomsLarger studyDepressed moodSymptomsChronic mood
2007
Predictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers
Absalom A, Lee M, Menon D, Sharar S, De Smet T, Halliday J, Ogden M, Corlett P, Honey G, Fletcher P. Predictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers. British Journal Of Anaesthesia 2007, 98: 615-623. PMID: 17389691, PMCID: PMC3838936, DOI: 10.1093/bja/aem063.Peer-Reviewed Original ResearchConceptsTarget-controlled infusionKetamine infusionHealthy volunteersLow-dose ketamine infusionPlasma concentration-time courseVenous blood samplesCognitive function testsConcentration-time courseFunction testsKetamine administrationTarget concentrationBlood samplesKetamine modelInfusionMore occasionsTCI deviceFunctional neuroimagingVolunteers